Skip to content

Study of enhanced external counterpulsation on renal function and its mechanism in patients after coronary angiography

Study of enhanced external counterpulsation on renal function and its mechanism in patients after coronary angiography

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069826
Enrollment
Unknown
Registered
2023-03-27
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast-induced nephropathy

Interventions

Normal renal functiontest team:enhanced external counterpulsation and Hydration therapy
Normal renal function control group:Hydration therapy
Renal insufficiency test group:: enhanced external counterpulsation and Hydration therapy
Renal insufficiency control group:Hydration therapy

Sponsors

Department of Cardiology, The Third Hospital of Mianyang, Sichuan Mental Health Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) voluntary participation in the trial and informed consent; (2) age> 18 years; (3) planning for CAG or PCI; (4) no relevant contraindications (e. g., contrast allergy, not eligible for EECP (see the guidelines for booster therapy))

Exclusion criteria

Exclusion criteria: (1) persons allergic to contrast agents; (2) lactation or pregnancy; (3) confirmed or suspected AKI; (4) use of contrast agent or nephrotoxic drugs within 1 week prior to enrollment; (5) severe renal insufficiency requiring hemodialysis; (6) intra-aortic balloon pump, acute heart failure, liver failure, connective tissue disease, arrhythmia, tumor, serious or nosocomial infectious disease, or a history of cardiogenic shock or cardiac arrest.(7) Enhanced extracorporeal anti-bo contraindications.

Design outcomes

Primary

MeasureTime frame
renal function;Hemorheology;hs-CRP?IL-6?TNF-a;Incidence rate of CIN;

Secondary

MeasureTime frame
ß2-MG;Urine Microprotein Series;Adverse reactions during EECP;FMD;

Countries

china

Contacts

Public ContactLanli

The Third Hospital of Mianyang

jia616819@sina.com18981113768

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026